Repligen Corporation (NASDAQ:RGEN) reported Q2 2018 earnings, coming in at $0.16 per share, missing Wall Street’s estimates of $0.18 per Share. Revenue for the quarter came in at $47.73 million beating analyst estimates of $45.84 million.
Thursday, August 2, 2018
Ultragenyx reported earnings of ($1.06) per share beat views
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported Q2 2018 earnings, coming in at ($1.06) per share, beating Wall Street’s estimates of ($2.08) per Share. Revenue for the quarter came in at $12.79 million missing the streets estimates of $5.63 million
Pacira Pharmaceuticals reported earnings of $0.24 per share beat views
Pacira Pharmaceuticals (NASDAQ:PCRX) reported Q2 2018 earnings, coming in at $0.24 per share, beating Wall Street’s estimates of $0.05 per Share. Revenue for the quarter came in at $84.10 million beating analyst estimates of $77.53 million.
Acceleron Pharma reported earnings of ($0.63) per share beat views
Acceleron Pharma (NASDAQ:XLRN) reported Q2 2018 earnings, coming in at ($0.63) per share, beating Wall Street’s estimates of ($0.65) per Share. Revenue for the quarter came in at $3.69 million beating analyst estimates of $3.37 million
Allscripts Healthcare Solutions reported earnings of $0.18 per share meet views
Allscripts Healthcare Solutions (NASDAQ:MDRX) reported Q2 2018 earnings, coming in at $0.18 per share, in-line Wall Street’s estimates of $0.18 per Share. Revenue for the quarter came in at $525.50 million missing the streets estimates of $536.93 million.
AMN Healthcare Services reported earnings of $0.83 per share beat views
AMN Healthcare Services (NYSE:AMN) reported Q2 2018 earnings, coming in at $0.83 per share, beating Wall Street’s estimates of $0.78 per Share. Revenue for the quarter came in at $558.10 million beating analyst estimates of $533.99 million.
Emergent Biosolutions reported earnings of $1.07 per share beat views
Emergent Biosolutions (NYSE:EBS) reported Q2 2018 earnings this Afternoon, coming in at $1.07 per share, beating Wall Street’s estimates of $0.89 per Share. Revenue for the quarter came in at $220.20 million beating analyst estimates of $208.94 million
Subscribe to:
Comments (Atom)